Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
Go back to Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program| Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) | Delayed: 2.16 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.16 | 52 Week High | $19.62 | |||
| Open | $2.16 | 52 Week Low | $7.65 | |||
| Day High | $2.16 | P/E | N/A | |||
| Day Low | $2.16 | EPS | $-0.22 | |||
| Volume | 17 | |||||
